Palouse Capital Management's Q3 and Q4 2022: A Look at the Top Holdings Changes
Ava Hoppe | 8 May, 2023
Palouse Capital Management, Inc. is a registered investment advisory firm that manages several portfolios comprised of different investments. One of the things Palouse does is file a 13F form with the Securities and Exchange Commission (SEC) to disclose its holdings at the end of each quarter.
This article will take a closer look at Palouse Capital Management's Q3 and Q4 2022 13F filings, specifically comparing their top holdings changes.
As of Q3 2022, Palouse held 33 unique issuers with an aggregate market value of $1.4 billion. As part of its strategy, Palouse bought and sold securities between Q3 and Q4, resulting in a smaller portfolio of 28 unique issuers and an aggregate market value of $1.3 billion.
Regeneron Pharmaceuticals and BlackRock Inc were the two highest-valued holdings at the end of Q3, with a combined value of $161.5 million. However, Palouse decreased its holdings on both companies, resulting in an approximately 45% decrease in total value.
Broadcom Inc and Thermo Fisher Scientific Inc were two of the biggest increases in holdings between Q3 and Q4. Palouse added over 6,400 shares in Broadcom and over 100 shares in Thermo Fisher. These two holdings combined made up 18% of Palouse's portfolio at the end of Q4, compared to being 8% at the end of Q3.
Another increase in holdings was NXP Semiconductors NV. Palouse added nearly 1,500 shares, resulting in an increase of 19% in total shares held. Lam Research Corporation, SPDR S&P 500 ETF TR, and Home Depot Inc also saw increases in shares held.
Despite holding fewer securities and a lower aggregate market value, Palouse's holdings in Q4 generated a higher percentage increase compared to Q3. In Q3, their holdings decreased by 7% while in Q4, their holdings increased by 9.8%.
In conclusion, Palouse Capital Management's Q3 and Q4 filings show a few significant changes in its holdings. While their two highest-valued holdings at the end of Q3 decreased in value, their increased holdings in Broadcom Inc, Thermo Fisher Scientific Inc, and NXP Semiconductors NV suggest that Palouse is gravitating more towards the technology and semiconductor industries.
Other Posts
- Cohen Klingenstein LLC Q2 2023 vs. Q3 2023: A Closer Look at 13F Holdings Changes
- Analyzing Zwj Investment Counsel Inc's 13F Holdings in Q3 vs. Q4 2022
- Analyzing Millrace Asset Group's Q3 2022 vs. Q4 2022 13F Holdings Comparison: Notable Changes in Equity Portfolio Holdings.
- Revolutionizing the Auto Glass Industry: PGW Auto Glass Integrates High-Tech Solutions with AutoglassCRM Acquisition
- Investment Fund Comparison: Analyzing Origin Asset Management LLP's Q3 2022 vs. Q4 2022 Holdings
- Equity Group Investments: Investor Consortium Partners with Baja Aqua-Farms to Promote Future Growth
- Bright Rock Capital Management's Q4 2022 vs. Q1 2023 Holdings Report: Analysis, Trends, and Insights
- Crestwood Advisors Group LLC Q4 2022 vs. Q1 2023 13F Holdings Comparison
- The Changing Tides of Fund Holdings: A Q3 vs. Q4 13F Comparison
- Radnor Capital Management, LLC Q3 2023 vs. Q4 2023 13F Holdings Comparison